SBFM
Sunshine Biopharma, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$758K
5Y Perf.-100.0%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
SBFM vs NUVB vs IMVT vs AGEN vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
NUVB
Nuvation Bio Inc.
Biotechnology
Market Cap$1.67B
5Y Perf.-51.8%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.-19.8%
AGEN
Agenus Inc.
Biotechnology
Market Cap$132M
5Y Perf.-95.7%
CRL
Charles River Laboratories International, Inc.
Medical - Diagnostics & Research
Market Cap$8.98B
5Y Perf.-16.9%
SBFM vs NUVB vs IMVT vs AGEN vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SBFM | NUVB | IMVT | AGEN | CRL |
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $758K | $1.67B | $5.53B | $132M | $8.98B |
| Revenue (TTM) | $36M | $143M | $0.00 | $114M | $4.03B |
| Net Income (TTM) | $-6M | $-146M | $-464M | $115K | $-185M |
| Gross Margin | 33.3% | 91.6% | — | 35.7% | 24.9% |
| Operating Margin | -17.9% | -105.0% | — | -17.7% | 11.8% |
| Forward P/E | — | — | — | 1.8x | 16.4x |
| Total Debt | $952K | $10M | $98K | $10M | $3.07B |
| Cash & Equiv. | $10M | $164M | $714M | $3M | $214M |
SBFM vs NUVB vs IMVT vs AGEN vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SBFM
NUVB
IMVT
AGEN
CRL
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| Sunshine Biopharma,… (SBFM) | 100 | 0.0 | -100.0% |
| Nuvation Bio Inc. (NUVB) | 100 | 48.2 | -51.8% |
| Immunovant, Inc. (IMVT) | 100 | 80.2 | -19.8% |
| Agenus Inc. (AGEN) | 100 | 4.3 | -95.7% |
| Charles River Labor… (CRL) | 100 | 83.1 | -16.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SBFM vs NUVB vs IMVT vs AGEN vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NUVB and AGEN are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Agenus Inc. is the stronger pick specifically for valuation and capital efficiency and operational efficiency and capital deployment. SBFM and IMVT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
SBFM
Sunshine Biopharma, Inc.
The Growth Play
SBFM ranks third and is worth considering specifically for growth exposure.
- Rev growth 44.7%, EPS growth 97.9%, 3Y rev CAGR 434.5%
- Beta 1.31 vs AGEN's 2.72
Best for: growth exposure
NUVB
Nuvation Bio Inc.
The Growth Leader
NUVB has the current edge in this matchup, primarily because of its strength in growth and momentum.
- 7.0% revenue growth vs IMVT's -21.3%
- +136.3% vs SBFM's -15.0%
Best for: growth and momentum
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 173.6% 10Y total return vs CRL's 119.2%
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
- Beta 1.37, current ratio 11.16x
- 3.2% margin vs NUVB's -102.1%
Best for: long-term compounding and sleep-well-at-night
AGEN
Agenus Inc.
The Income Pick
AGEN is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 1 yrs, beta 2.72
- Lower P/E (1.8x vs 16.4x)
- 0.1% ROA vs IMVT's -44.1%
Best for: income & stability
CRL
Charles River Laboratories International, Inc.
The Healthcare Pick
Among these 5 stocks, CRL doesn't own a clear edge in any measured category.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVB | 7.0% revenue growth vs IMVT's -21.3% |
| Value | AGEN | Lower P/E (1.8x vs 16.4x) |
| Quality / Margins | IMVT | 3.2% margin vs NUVB's -102.1% |
| Stability / Safety | SBFM | Beta 1.31 vs AGEN's 2.72 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | NUVB | +136.3% vs SBFM's -15.0% |
| Efficiency (ROA) | AGEN | 0.1% ROA vs IMVT's -44.1% |
SBFM vs NUVB vs IMVT vs AGEN vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2025
FY 2025
SBFM vs NUVB vs IMVT vs AGEN vs CRL — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNUVBLAGGINGAGEN
Who Leads Where
NUVB leads in 2 of 6 categories
CRL leads 1 • SBFM leads 0 • IMVT leads 0 • AGEN leads 0 • 2 tied
Explore the data ↓AGENAgenus Inc.
0leads
IMVTImmunovant, Inc.
0leads
SBFMSunshine Biopharma, I…
0leads
CRLCharles River Laborat…
1leads
NUVBNuvation Bio Inc.
2leads
6 Total Categories
CATEGORYLEADERvs CRLvs SBFMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NUVB3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRL4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVB3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NUVB leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CRL and IMVT operate at a comparable scale, with $4.0B and $0 in trailing revenue. AGEN is the more profitable business, keeping 0.1% of every revenue dollar as net income compared to NUVB's -102.1%. On growth, NUVB holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SBFMSunshine Biopharm… | NUVBNuvation Bio Inc. | IMVTImmunovant, Inc. | AGENAgenus Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $36M | $143M | $0 | $114M | $4.0B |
| EBITDAEarnings before interest/tax | -$6M | -$145M | -$487M | -$10M | $757M |
| Net IncomeAfter-tax profit | -$6M | -$146M | -$464M | $115,000 | -$185M |
| Free Cash FlowCash after capex | -$9M | -$126M | -$423M | -$159M | $391M |
| Gross MarginGross profit ÷ Revenue | +33.3% | +91.6% | — | +35.7% | +24.9% |
| Operating MarginEBIT ÷ Revenue | -17.9% | -105.0% | — | -17.7% | +11.8% |
| Net MarginNet income ÷ Revenue | -17.4% | -102.1% | — | +0.1% | -4.6% |
| FCF MarginFCF ÷ Revenue | -26.1% | -88.1% | — | -139.1% | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.2% | +26.0% | — | +27.5% | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +21.5% | +106.3% | +19.7% | +85.3% | -160.0% |
NUVB leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — SBFM and AGEN each lead in 2 of 4 comparable metrics.
Valuation Metrics
| Metric | SBFMSunshine Biopharm… | NUVBNuvation Bio Inc. | IMVTImmunovant, Inc. | AGENAgenus Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Market CapShares × price | $757,819 | $1.7B | $5.5B | $132M | $9.0B |
| Enterprise ValueMkt cap + debt − cash | -$8M | $1.5B | $4.8B | $140M | $11.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.15x | -8.03x | -9.97x | -1102.94x | -62.52x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 1.79x | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 12.98x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 26.61x | — | 1.16x | 2.24x |
| Price / BookPrice ÷ Book value/share | 0.03x | 5.38x | 5.83x | — | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 17.31x |
Evenly matched — SBFM and AGEN each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
CRL leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
CRL delivers a -5.7% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs SBFM's 1/9, reflecting solid financial health.
| Metric | SBFMSunshine Biopharm… | NUVBNuvation Bio Inc. | IMVTImmunovant, Inc. | AGENAgenus Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -24.6% | -44.1% | -47.1% | — | -5.7% |
| ROA (TTM)Return on assets | -19.7% | -23.8% | -44.1% | +0.1% | -2.5% |
| ROICReturn on invested capital | -42.9% | -54.3% | — | — | +6.3% |
| ROCEReturn on capital employed | -25.2% | -42.8% | -66.1% | — | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 2 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.04x | 0.03x | 0.00x | — | 0.95x |
| Net DebtTotal debt minus cash | -$9M | -$154M | -$714M | $7M | $2.9B |
| Cash & Equiv.Liquid assets | $10M | $164M | $714M | $3M | $214M |
| Total DebtShort + long-term debt | $952,480 | $10M | $98,000 | $10M | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | -757.53x | -162.11x | — | 1.11x | 6.38x |
CRL leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NUVB leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $1 for SBFM. Over the past 12 months, NUVB leads with a +136.3% total return vs SBFM's -15.0%. The 3-year compound annual growth rate (CAGR) favors NUVB at 43.8% vs SBFM's -89.8% — a key indicator of consistent wealth creation.
| Metric | SBFMSunshine Biopharm… | NUVBNuvation Bio Inc. | IMVTImmunovant, Inc. | AGENAgenus Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -15.6% | -43.8% | +5.1% | +16.1% | -10.1% |
| 1-Year ReturnPast 12 months | -15.0% | +136.3% | +96.1% | +27.1% | +32.8% |
| 3-Year ReturnCumulative with dividends | -99.9% | +197.5% | +40.9% | -88.2% | -4.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -58.3% | +62.4% | -93.9% | -46.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | -51.8% | +173.6% | -94.3% | +119.2% |
| CAGR (3Y)Annualised 3-year return | -89.8% | +43.8% | +12.1% | -51.0% | -1.4% |
NUVB leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SBFM and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
SBFM is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs SBFM's 44.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SBFMSunshine Biopharm… | NUVBNuvation Bio Inc. | IMVTImmunovant, Inc. | AGENAgenus Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 2.04x | 1.37x | 2.72x | 1.52x |
| 52-Week HighHighest price in past year | $2.43 | $9.75 | $30.09 | $7.34 | $228.88 |
| 52-Week LowLowest price in past year | $0.95 | $1.57 | $13.36 | $2.71 | $131.30 |
| % of 52W HighCurrent price vs 52-week peak | +44.4% | +49.4% | +90.5% | +51.1% | +79.5% |
| RSI (14)Momentum oscillator 0–100 | 56.2 | 59.1 | 60.2 | 48.8 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 38K | 4.3M | 1.4M | 814K | 806K |
Evenly matched — SBFM and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NUVB as "Buy", IMVT as "Buy", AGEN as "Buy", CRL as "Buy". Consensus price targets imply 157.3% upside for NUVB (target: $12) vs 12.9% for CRL (target: $205).
| Metric | SBFMSunshine Biopharm… | NUVBNuvation Bio Inc. | IMVTImmunovant, Inc. | AGENAgenus Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $12.40 | $45.50 | $7.33 | $205.43 |
| # AnalystsCovering analysts | — | 9 | 23 | 11 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% | 0.0% | +0.1% | +4.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NUVB leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CRL leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallNuvation Bio Inc. (NUVB)Leads 2 of 6 categories
Loading custom metrics...
SBFM vs NUVB vs IMVT vs AGEN vs CRL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SBFM or NUVB or IMVT or AGEN or CRL a better buy right now?
For growth investors, Nuvation Bio Inc.
(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SBFM or NUVB or IMVT or AGEN or CRL?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -100. 0% for Sunshine Biopharma, Inc. (SBFM). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus SBFM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SBFM or NUVB or IMVT or AGEN or CRL?
By beta (market sensitivity over 5 years), Sunshine Biopharma, Inc.
(SBFM) is the lower-risk stock at 1. 31β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 107% more volatile than SBFM relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SBFM or NUVB or IMVT or AGEN or CRL?
By revenue growth (latest reported year), Nuvation Bio Inc.
(NUVB) is pulling ahead at 699. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, SBFM leads at 434. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SBFM or NUVB or IMVT or AGEN or CRL?
Agenus Inc.
(AGEN) is the more profitable company, earning 0. 1% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SBFM or NUVB or IMVT or AGEN or CRL more undervalued right now?
On forward earnings alone, Agenus Inc.
(AGEN) trades at 1. 8x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 14. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUVB: 157. 3% to $12. 40.
07Which pays a better dividend — SBFM or NUVB or IMVT or AGEN or CRL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SBFM or NUVB or IMVT or AGEN or CRL better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +173. 6%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SBFM and NUVB and IMVT and AGEN and CRL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SBFM is a small-cap high-growth stock; NUVB is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(SBFM: 1.2% · NUVB: 2598.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.